# AbbVie: Phase 3 study closed enrollment, 167 enrolled (Non-Small Cell Lung Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
| NCT ID | NCT06236438 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 167 |
| Site countries | United States, Australia, Belgium, Chile, France, Israel, Japan, Netherlands, Puerto Rico, Spain, Taiwan, Turkey (Türkiye) |
| Posted | 2024-02-01 |
| Planned start | 2024-04-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 167 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06236438). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.